"
ABSTRAKLatar belakang: Laringomalasia merupakan kondisi kelemahan struktur
supraglotis saat inspirasi sehingga menyebabkan sumbatan jalan nafas atas dan
menimbulkan gejala stridor inspirasi. Stridor semakin memburuk pada posisi
terlentang. Penyakit penyerta laringomalasia umumnya adalah refluks
laringofaring (RLF) yaitu 25-68%. RLF adalah pergerakan isi lambung secara
retrograd menuju laring-faring, menimbulkan gejala dan tanda klinis yang
bervariasi. Pemberian omeperazol dapat memperbaiki gejala regurgitasi dan
stridor serta memperpendek durasi perjalanan alamiah laringomalasia
Tujuan: Mengetahui efektifitas omeperazol pada bayi dan anak dengan
laringomalasia, mengetahui prevalensi RLF pada laringomalasia, ada tidaknya
RLF berdasar nilai reflux finding score (RFS) menurut Belafsky dan mengetahui
berat ringan gejala laringomalasia berdasar nilai laryngomalacia symptom score
(LSS).
Metode: Uji controlled trials pada 65 subyek laringomalasia, dibagi kedalam
kelompok 42 subyek yang mendapat omeperazol 2 x 2 mg/kg/bb dan 23 subyek
yang mendapat plasebo selama 3 bulan
Hasil : Kelompok omeperazol dengan gejala berat 58,8% mengalami perbaikan
dibanding kelompok plasebo 66,7% dengan nilai p = 0,716. Kelompok
omeperazol dengan RLF positif 58,3% mengalami perbaikan dibanding
kelompok plasebo 75% dengan nilai p = 1.0
Simpulan : Prevalensi RLF positif sebesar 24,6% dan gejala berat sebesar 44,6%.
Efektifitas pemberian omeperazol selama 3 bulan belum terbukti efektif dibanding
plasebo berdasarkan perbaikan nilai LSS, RFS dan status gizi. Namun hasil
tersebut hanya berlaku sebagai kesimpulan penelitian pendahuluan karena tidak
optimalnya besar sampel dan randomisasi subyek. Perlu penelitian lanjutan untuk
membuktikan efektifitas omeperazol pada perbaikan skor LSS, skor RFS dan
status gizi bayi dan anak dengan laringomalasia
ABSTRACTBackground: laryngomalacia is condition of floopy supraglottis stucture in
respiratory that trigger obstruction the upper airway and it causes symptom stridor
inspiratory. Stridor can get worse in face up position. In general, the comorbidity
of laryngomalacia is laryngopharyngeal reflux (LPR) about 25-68%. LPR is the
movement of gaster retrogradely toward laryngopharyngeal and it triggers various
symptom and clinical sign. The giving of omeperazole can improve the symptom
of regurgitation and stridor and shorten the duration of natural disease of
laryngomalacia
Objective: Knowing the effectivity of giving omeperazole to the babies and
children with laryngomalacia, knowing the prevalance of LPR to the
laryngomalacia, knowing the positibility of LPR based on the value of reflux
finding score (RFS) according to Belafsky and knowing severity of symptom
laryngomalacia based on the value of laryngomalacia symptom score (LSS).
Method: Test on controlled trials on 65 samples with laryngomalacia and is
divided into 42 groups that have been given omeperazole 2x2 mg/kg/bw and 23
samples that have been given placebo for 3 month
Result: Omeperazol groups with severe symptom showed the improvement of
58,8% compared to placebo groups 66,7% with p = 0.716. Omeperazole groups
with RLF positive showed the improvement of 58,3% compared to placebo
groups 75 % with p = 1.0
Conclusion: The Prevalence of positive LPR based on RFS is 24,6% and with
severe symptom is 44,6%. The effectivity of giving omeperazole for 3 month has
not proved effective compared to placebo based on the improvement of value
LSS, RFS and nutrition status. However such result is only valid for the
conclusion of initial research because the size of samples were not either optimal
or randomized. It is necessary to conduct research continution to prove the
effectivity of giving omeperazole on the improvement of LSS score, RFS score
and nutrition status of babies and children with laryngomalacia"
